Logo image of INMB

INMUNE BIO INC (INMB) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:INMB - US45782T1051 - Common Stock

1.66 USD
-0.07 (-4.05%)
Last: 12/29/2025, 8:00:02 PM
1.63 USD
-0.03 (-1.81%)
After Hours: 12/29/2025, 8:00:02 PM
Fundamental Rating

3

INMB gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 530 industry peers in the Biotechnology industry. While INMB seems to be doing ok healthwise, there are quite some concerns on its profitability. INMB is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

INMB had negative earnings in the past year.
INMB had a negative operating cash flow in the past year.
In the past 5 years INMB always reported negative net income.
In the past 5 years INMB always reported negative operating cash flow.
INMB Yearly Net Income VS EBIT VS OCF VS FCFINMB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M -40M

1.2 Ratios

INMB's Return On Assets of -149.55% is on the low side compared to the rest of the industry. INMB is outperformed by 85.47% of its industry peers.
The Return On Equity of INMB (-196.58%) is worse than 68.11% of its industry peers.
Industry RankSector Rank
ROA -149.55%
ROE -196.58%
ROIC N/A
ROA(3y)-64.13%
ROA(5y)-50.5%
ROE(3y)-85.07%
ROE(5y)-64.85%
ROIC(3y)N/A
ROIC(5y)N/A
INMB Yearly ROA, ROE, ROICINMB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 -200 -400

1.3 Margins

INMB does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
INMB Yearly Profit, Operating, Gross MarginsINMB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100K -200K -300K

More info and screens

6

2. Health

2.1 Basic Checks

The number of shares outstanding for INMB has been increased compared to 1 year ago.
INMB has more shares outstanding than it did 5 years ago.
INMB has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
INMB Yearly Shares OutstandingINMB Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M
INMB Yearly Total Debt VS Total AssetsINMB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

2.2 Solvency

INMB has an Altman-Z score of -7.84. This is a bad value and indicates that INMB is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of INMB (-7.84) is worse than 67.74% of its industry peers.
INMB has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -7.84
ROIC/WACCN/A
WACCN/A
INMB Yearly LT Debt VS Equity VS FCFINMB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M -40M 60M 80M

2.3 Liquidity

A Current Ratio of 4.17 indicates that INMB has no problem at all paying its short term obligations.
INMB has a Current ratio (4.17) which is comparable to the rest of the industry.
INMB has a Quick Ratio of 4.17. This indicates that INMB is financially healthy and has no problem in meeting its short term obligations.
INMB has a Quick ratio (4.17) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 4.17
Quick Ratio 4.17
INMB Yearly Current Assets VS Current LiabilitesINMB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

More info and screens

4

3. Growth

3.1 Past

INMB shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 2.75%.
Looking at the last year, INMB shows a quite strong growth in Revenue. The Revenue has grown by 19.05% in the last year.
Measured over the past years, INMB shows a very negative growth in Revenue. The Revenue has been decreasing by -57.31% on average per year.
EPS 1Y (TTM)2.75%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%60%
Revenue 1Y (TTM)19.05%
Revenue growth 3Y-57.31%
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

INMB is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 15.69% yearly.
INMB is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 496.62% yearly.
EPS Next Y7.18%
EPS Next 2Y24.58%
EPS Next 3Y15.22%
EPS Next 5Y15.69%
Revenue Next Year376.19%
Revenue Next 2Y2522%
Revenue Next 3Y760.33%
Revenue Next 5Y496.62%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
INMB Yearly Revenue VS EstimatesINMB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 50M 100M 150M 200M 250M
INMB Yearly EPS VS EstimatesINMB Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for INMB. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for INMB. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
INMB Price Earnings VS Forward Price EarningsINMB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
INMB Per share dataINMB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -1 -2

4.3 Compensation for Growth

INMB's earnings are expected to grow with 15.22% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y24.58%
EPS Next 3Y15.22%

More info and screens

0

5. Dividend

5.1 Amount

INMB does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

INMUNE BIO INC

NASDAQ:INMB (12/29/2025, 8:00:02 PM)

After market: 1.63 -0.03 (-1.81%)

1.66

-0.07 (-4.05%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)10-30 2025-10-30/amc
Earnings (Next)03-25 2026-03-25/amc
Inst Owners17.51%
Inst Owner Change-18.33%
Ins Owners17.01%
Ins Owner Change0%
Market Cap44.14M
Revenue(TTM)50.00K
Net Income(TTM)-49.89M
Analysts76.67
Price Target5.36 (222.89%)
Short Float %14.18%
Short Ratio7.33
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-71.06%
Min EPS beat(2)-169.71%
Max EPS beat(2)27.6%
EPS beat(4)3
Avg EPS beat(4)-26.11%
Min EPS beat(4)-169.71%
Max EPS beat(4)27.6%
EPS beat(8)4
Avg EPS beat(8)-14.65%
EPS beat(12)6
Avg EPS beat(12)-146.22%
EPS beat(16)10
Avg EPS beat(16)-103.87%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-37.5%
PT rev (3m)-37.5%
EPS NQ rev (1m)16.09%
EPS NQ rev (3m)25.89%
EPS NY rev (1m)-23.55%
EPS NY rev (3m)-23.55%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)25%
Revenue NY rev (3m)50.02%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 882.79
P/FCF N/A
P/OCF N/A
P/B 1.74
P/tB 1.74
EV/EBITDA N/A
EPS(TTM)-2.12
EYN/A
EPS(NY)-0.95
Fwd EYN/A
FCF(TTM)-1.2
FCFYN/A
OCF(TTM)-1.17
OCFYN/A
SpS0
BVpS0.95
TBVpS0.95
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -149.55%
ROE -196.58%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-64.13%
ROA(5y)-50.5%
ROE(3y)-85.07%
ROE(5y)-64.85%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.17
Quick Ratio 4.17
Altman-Z -7.84
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)2.75%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%60%
EPS Next Y7.18%
EPS Next 2Y24.58%
EPS Next 3Y15.22%
EPS Next 5Y15.69%
Revenue 1Y (TTM)19.05%
Revenue growth 3Y-57.31%
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year376.19%
Revenue Next 2Y2522%
Revenue Next 3Y760.33%
Revenue Next 5Y496.62%
EBIT growth 1Y15.52%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-123.37%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-117.08%
OCF growth 3YN/A
OCF growth 5YN/A

INMUNE BIO INC / INMB FAQ

What is the ChartMill fundamental rating of INMUNE BIO INC (INMB) stock?

ChartMill assigns a fundamental rating of 3 / 10 to INMB.


Can you provide the valuation status for INMUNE BIO INC?

ChartMill assigns a valuation rating of 0 / 10 to INMUNE BIO INC (INMB). This can be considered as Overvalued.


How profitable is INMUNE BIO INC (INMB) stock?

INMUNE BIO INC (INMB) has a profitability rating of 0 / 10.


Can you provide the financial health for INMB stock?

The financial health rating of INMUNE BIO INC (INMB) is 6 / 10.


Can you provide the expected EPS growth for INMB stock?

The Earnings per Share (EPS) of INMUNE BIO INC (INMB) is expected to grow by 7.18% in the next year.